

# Ruben Niesvizky

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11766889/publications.pdf>

Version: 2024-02-01

197  
papers

9,417  
citations

70961

41  
h-index

39575

94  
g-index

197  
all docs

197  
docs citations

197  
times ranked

7381  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America. <i>New England Journal of Medicine</i> , 2007, 357, 2133-2142.	13.9	1,186
2	Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 372, 142-152.	13.9	1,144
3	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	3.3	664
4	Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2010, 28, 4976-4984.	0.8	358
5	International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 587-600.	0.8	330
6	Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1327-1337.	5.1	320
7	Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. <i>Haematologica</i> , 2013, 98, 1753-1761.	1.7	300
8	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. <i>Blood</i> , 2011, 117, 6063-6073.	0.6	282
9	Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. <i>Lancet Oncology</i> , The, 2014, 15, 1503-1512.	5.1	233
10	Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2009, 15, 5250-5257.	3.2	228
11	A Novel Orally Active Small Molecule Potently Induces G1 Arrest in Primary Myeloma Cells and Prevents Tumor Growth by Specific Inhibition of Cyclin-Dependent Kinase 4/6. <i>Cancer Research</i> , 2006, 66, 7661-7667.	0.4	209
12	Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. <i>Blood</i> , 2009, 114, 1729-1735.	0.6	203
13	Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. <i>Blood</i> , 2014, 124, 1047-1055.	0.6	185
14	IMWG consensus on maintenance therapy in multiple myeloma. <i>Blood</i> , 2012, 119, 3003-3015.	0.6	178
15	BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. <i>Blood</i> , 2008, 111, 1101-1109.	0.6	175
16	A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. <i>Blood</i> , 2012, 119, 2764-2767.	0.6	143
17	Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens. <i>Journal of Clinical Oncology</i> , 2015, 33, 3921-3929.	0.8	131
18	Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. <i>Blood</i> , 2013, 122, 3122-3128.	0.6	126

#	ARTICLE	IF	CITATIONS
19	Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. <i>Cancer</i> , 2011, 117, 336-342.	2.0	116
20	Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. <i>Blood</i> , 2016, 128, 1174-1180.	0.6	110
21	Stem Cell Mobilization with Cyclophosphamide Overcomes the Suppressive Effect of Lenalidomide Therapy on Stem Cell Collection in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 795-798.	2.0	106
22	Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. <i>European Journal of Haematology</i> , 2009, 82, 426-432.	1.1	104
23	Mutually Exclusive Cyclin-Dependent Kinase 4/Cyclin D1 and Cyclin-Dependent Kinase 6/Cyclin D2 Pairing Inactivates Retinoblastoma Protein and Promotes Cell Cycle Dysregulation in Multiple Myeloma. <i>Cancer Research</i> , 2005, 65, 11345-11353.	0.4	101
24	The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2008, 143, 46-53.	1.2	94
25	Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2019, 133, 1953-1963.	0.6	94
26	Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467 T <i>Journal of Haematology</i> , 2013, 163, 478-486.	1.2	89
27	Prolonged early G1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4. <i>Blood</i> , 2012, 120, 1095-1106.	0.6	88
28	Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing frontline lenalidomide and dexamethasone therapy. <i>British Journal of Haematology</i> , 2007, 138, 640-643.	1.2	82
29	Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. <i>British Journal of Haematology</i> , 2009, 146, 164-170.	1.2	79
30	Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma. <i>Clinical Cancer Research</i> , 2013, 19, 2248-2256.	3.2	78
31	Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3921-3930.	0.8	70
32	Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2015, 56, 3320-3328.	0.6	67
33	Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. <i>Leukemia and Lymphoma</i> , 2009, 50, 559-565.	0.6	66
34	Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. <i>Leukemia and Lymphoma</i> , 2007, 48, 2330-2337.	0.6	60
35	Survival Effect of Venous Thromboembolism in Patients With Multiple Myeloma Treated With Lenalidomide and High-Dose Dexamethasone. <i>Journal of Clinical Oncology</i> , 2010, 28, 132-135.	0.8	58
36	Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. <i>British Journal of Haematology</i> , 2017, 177, 404-413.	1.2	58

#	ARTICLE	IF	CITATIONS
37	Germline Lysine-Specific Demethylase 1 (<i>LSD1/KDM1A</i>) Mutations Confer Susceptibility to Multiple Myeloma. <i>Cancer Research</i> , 2018, 78, 2747-2759.	0.4	56
38	Clarithromycin (Biaxin)â€lenalidomideâ€lowâ€dose dexamethasone (BiRd) versus lenalidomideâ€lowâ€dose dexamethasone (Rd) for newly diagnosed myeloma. <i>American Journal of Hematology</i> , 2010, 85, 664-669.	2.0	49
39	Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 522-530.e1.	0.2	47
40	IgM myeloma: A multicenter retrospective study of 134 patients. <i>American Journal of Hematology</i> , 2017, 92, 746-751.	2.0	45
41	Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. <i>Leukemia</i> , 2019, 33, 1736-1746.	3.3	45
42	Gallium nitrate in multiple myeloma: Prolonged survival in a cohort of patients with advanced-stage disease. <i>Seminars in Oncology</i> , 2003, 30, 20-24.	0.8	44
43	A Phase I Humanized Anti-CD40 Monoclonal Antibody (SGN-40) in Patients with Multiple Myeloma.. <i>Blood</i> , 2005, 106, 2572-2572.	0.6	44
44	Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. <i>Lancet Haematology</i> ,the, 2022, 9, e143-e161.	2.2	44
45	BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma. <i>Blood</i> , 2013, 121, 1982-1985.	0.6	35
46	CDK2 Phosphorylation of Smad2 Disrupts TGF-Î² Transcriptional Regulation in Resistant Primary Bone Marrow Myeloma Cells. <i>Journal of Immunology</i> , 2009, 182, 1810-1817.	0.4	34
47	Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR. <i>Blood</i> , 2019, 133, 147-155.	0.6	33
48	Clinical characteristics of patients with relapsed multiple myeloma. <i>Cancer Treatment Reviews</i> , 2015, 41, 827-835.	3.4	30
49	Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay. <i>British Journal of Haematology</i> , 2016, 173, 884-895.	1.2	29
50	IgG4 plasma cell myeloma: new insights into the pathogenesis of IgG4-related disease. <i>Modern Pathology</i> , 2014, 27, 375-381.	2.9	28
51	Oprozomib, Pomalidomide, and Dexamethasone (OPomd) in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Initial Results of a Phase 1b Study (NCT01999335). <i>Blood</i> , 2015, 126, 378-378.	0.6	26
52	How lenalidomide is changing the treatment of patients with multiple myeloma. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, S23-S35.	2.0	24
53	Hematogenous extramedullary relapse in multiple myeloma â€a multicenter retrospective study in 127 patients. <i>American Journal of Hematology</i> , 2019, 94, 1132-1140.	2.0	24
54	Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization. <i>Clinical Cancer Research</i> , 2013, 19, 1534-1546.	3.2	22

#	ARTICLE	IF	CITATIONS
55	Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2018, 59, 2588-2594.	0.6	22
56	Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2019, 134, 140-140.	0.6	22
57	Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study. <i>British Journal of Haematology</i> , 2016, 175, 884-891.	1.2	21
58	Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 570-578.e1.	0.2	20
59	High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 2027-2038.	1.3	20
60	A phase 1b study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed/ refractory multiple myeloma (RRMM): Preliminary results.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8539-8539.	0.8	19
61	Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma. <i>Leukemia Research</i> , 2014, 38, 517-524.	0.4	18
62	Hematology and oncology clinical care during the coronavirus disease 2019 pandemic. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 349-354.	157.7	18
63	Dacetuzumab (SGN-40), Lenalidomide, and Weekly Dexamethasone in Relapsed or Refractory Multiple Myeloma: Multiple Responses Observed in a Phase 1b Study.. <i>Blood</i> , 2009, 114, 2870-2870.	0.6	18
64	Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results. <i>Blood</i> , 2014, 124, 82-82.	0.6	18
65	ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD®) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study). <i>Blood</i> , 2015, 126, 3040-3040.	0.6	18
66	Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. <i>Blood Advances</i> , 2020, 4, 5449-5459.	2.5	17
67	Complications of Multiple Myeloma Therapy, Part 2: Risk Reduction and Management of Venous Thromboembolism, Osteonecrosis of the Jaw, Renal Complications, and Anemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, S-13-S-20.	2.3	16
68	Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment. <i>Cancer Treatment Reviews</i> , 2012, 38, 1012-1019.	3.4	16
69	Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis. <i>Blood Cancer Journal</i> , 2020, 10, 35.	2.8	16
70	Weekly Dosing of the Investigational Oral Proteasome Inhibitor MLN9708 in Patients with Relapsed and/or Refractory Multiple Myeloma: Results From a Phase 1 Dose-Escalation Study. <i>Blood</i> , 2011, 118, 816-816.	0.6	16
71	Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study). <i>Blood</i> , 2016, 128, 3307-3307.	0.6	16
72	Best practices in the management of newly diagnosed multiple myeloma patients who will not undergo transplant. <i>Oncology</i> , 2010, 24, 14-21.	0.4	15

#	ARTICLE	IF	CITATIONS
73	Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. <i>Hematological Oncology</i> , 2020, 38, 353-362.	0.8	14
74	Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. <i>Blood Cancer Journal</i> , 2021, 11, 101.	2.8	14
75	Lenalidomide (L) in Combination with Dexamethasone (D) Significantly Improves Time to Progression (TTP) in Non-Stem Cell Transplant Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM): Analysis from MM-009 and MM-010 Randomized Phase III Clinical Trials.. <i>Blood</i> , 2006, 108, 3554-3554.	0.6	14
76	Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 288-293.	2.0	13
77	Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis. <i>Blood</i> , 2011, 118, 1876-1876.	0.6	13
78	Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies. <i>Blood</i> , 2019, 134, 5329-5329.	0.6	12
79	Results of a Phase I Trial of SGN-40 (Anti-huCD40 mAb) in Patients with Relapsed Multiple Myeloma.. <i>Blood</i> , 2006, 108, 3576-3576.	0.6	12
80	A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma. <i>Blood</i> , 2012, 120, 4029-4029.	0.6	12
81	Molecular Predictors of Outcome and Drug Response in Multiple Myeloma: An Interim Analysis of the Mmrf CoMMpass Study. <i>Blood</i> , 2016, 128, 194-194.	0.6	12
82	Induction of sequential G1 arrest and synchronous S phase entry by reversible CDK4/CDK6 inhibition sensitizes myeloma cells for cytotoxic killing through loss of IRF-4.. <i>Blood</i> , 2009, 114, 299-299.	0.6	12
83	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, 503-509.	2.0	11
84	ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2012, 120, 77-77.	0.6	11
85	A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 930-937.	2.0	10
86	Population Pharmacokinetics and Exposureâ€“Response Relationship of Carfilzomib in Patients With Multiple Myeloma. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 663-677.	1.0	10
87	Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma. <i>Blood Advances</i> , 2019, 3, 603-611.	2.5	10
88	Phase I Study of Lorvotuzumab Mertansine (IMGN901) In Combination with Lenalidomide and Dexamethasone In Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma - A Preliminary Safety and Efficacy Analysis of the Combination. <i>Blood</i> , 2010, 116, 1934-1934.	0.6	10
89	ClaPD (Clarithromycin/[BiaxinÂ®], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2011, 118, 635-635.	0.6	10
90	Phase Ib Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM).. <i>Blood</i> , 2009, 114, 304-304.	0.6	9



#	ARTICLE	IF	CITATIONS
91	Patient-Reported Quality of Life (QoL) in Elderly, Newly Diagnosed Multiple Myeloma (MM) Patients Receiving Bortezomib-Based Combinations: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study. <i>Blood</i> , 2011, 118, 1864-1864.	0.6	9
92	Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study. <i>Blood</i> , 2011, 118, 478-478.	0.6	9
93	Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma. <i>Blood Advances</i> , 2021, 5, 367-376.	2.5	8
94	Randomized Multicenter Phase 3 Trial of High-Dose Dexamethasone (dex) with or without Oblimersen Sodium (G3139; Bcl-2 antisense; Genasense) for Patients with Advanced Multiple Myeloma (MM).. <i>Blood</i> , 2004, 104, 1477-1477.	0.6	8
95	Multicenter Phase II Trial of the Histone Deacetylase Inhibitor Depsipeptide (FK228) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM).. <i>Blood</i> , 2005, 106, 2574-2574.	0.6	8
96	Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866). <i>Blood</i> , 2015, 126, 30-30.	0.6	8
97	Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391). <i>Blood</i> , 2015, 126, 731-731.	0.6	8
98	Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 825-833.	0.2	7
99	Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies. <i>Journal of Clinical Investigation</i> , 2017, 127, 2066-2080.	3.9	7
100	Cardiac and Pulmonary Safety Profile of Single-Agent Carfilzomib From Four Phase 2 Studies in Patients with Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , 2012, 120, 4037-4037.	0.6	7
101	Sequence Impact Of Pomalidomide and Carfilzomib On Treatment Response In Relapsed Multiple Myeloma. <i>Blood</i> , 2013, 122, 1954-1954.	0.6	7
102	Inhibition of CDK4/CDK6 Sensitizes Myeloma to IMiD By Reducing the MEIS2 to Cereblon Ratio That Accelerates IKZF1 and IKZF3 Degradation. <i>Blood</i> , 2015, 126, 500-500.	0.6	7
103	Extended Survival in Advanced-Stage Multiple Myeloma Patients Treated with Gallium Nitrate. <i>Leukemia and Lymphoma</i> , 2002, 43, 603-605.	0.6	6
104	Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. <i>Leukemia and Lymphoma</i> , 2018, 59, 1364-1374.	0.6	6
105	Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Myeloma Receiving Daratumumab and Pomalidomide. <i>Blood</i> , 2019, 134, 4876-4876.	0.6	6
106	Phase I Study of Carfilzomib in Patients (Pts) with Relapsed and Refractory Multiple Myeloma (MM) and Varying Degrees of Renal Insufficiency.. <i>Blood</i> , 2009, 114, 3877-3877.	0.6	6
107	Pooled Safety Analysis From Phase (Ph) 1 and 2 Studies of Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (MM). <i>Blood</i> , 2010, 116, 1954-1954.	0.6	6
108	Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy In Relapsed Or Refractory Multiple Myeloma. <i>Blood</i> , 2013, 122, 1955-1955.	0.6	6

#	ARTICLE	IF	CITATIONS
109	Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study. <i>Blood</i> , 2015, 126, 377-377.	0.6	6
110	Novel agents in myeloma: An exciting saga. <i>Cancer</i> , 2009, 115, 236-242.	2.0	5
111	Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publicationsâ€“2. <i>Mayo Clinic Proceedings</i> , 2010, 85, 197-199.	1.4	5
112	A phase 1b study of onceâ€“weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 226-233.	2.0	5
113	Caspase-8 Regulates the Antimyeloma Activity of Bortezomib and Lenalidomide. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 379, 303-309.	1.3	5
114	A Phase I Trial of PD 0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma.. <i>Blood</i> , 2009, 114, 1877-1877.	0.6	5
115	A Phase I Study of PD 0332991: Complete CDK4/6 Inhibition and Tumor Response In Sequential Combination with Bortezomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2010, 116, 860-860.	0.6	5
116	Phase 1/2 Study of Oral MLN9708, A Novel, Investigational Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 479-479.	0.6	5
117	Effect of Renal and Hepatic Function on Pomalidomide Dose in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 4754-4754.	0.6	5
118	Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study Endeavor (NCT01568866) According to Age Subgroup. <i>Blood</i> , 2015, 126, 1844-1844.	0.6	5
119	High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma. <i>Blood</i> , 2015, 126, 4258-4258.	0.6	5
120	Carfilzomib Induction with Lenalidomide and Clarithromycin Consolidation and Lenalidomide Maintenance (CarBiRD) for Multiple Myeloma (MM). <i>Blood</i> , 2016, 128, 4518-4518.	0.6	5
121	SEA-BCMA, an Investigational Nonfucosylated Monoclonal Antibody: Ongoing Results of a Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001). <i>Blood</i> , 2021, 138, 2740-2740.	0.6	5
122	Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 539-545.	2.0	4
123	Caspase-8 Inhibition Prevents the Cleavage and Degradation of E3 Ligase Substrate Receptor Cereblon and Potentiates Its Biological Function. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 605989.	1.8	4
124	Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial. <i>Blood</i> , 2019, 134, 694-694.	0.6	4
125	Phase 3b UPFRONT Study: Interim Results From a Community Practice-Based Prospective Randomized Trial Evaluating Three Bortezomib-Based Regimens in Elderly, Newly Diagnosed Multiple Myeloma Patients.. <i>Blood</i> , 2009, 114, 129-129.	0.6	4
126	CHOP-R + Bortezomib as Initial Therapy for Mantle Cell Lymphoma (MCL).. <i>Blood</i> , 2009, 114, 2682-2682.	0.6	4



#	ARTICLE	IF	CITATIONS
127	Long-Term Treatment and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM). <i>Blood</i> , 2010, 116, 1953-1953.	0.6	4
128	Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib. <i>Blood</i> , 2015, 126, 4232-4232.	0.6	4
129	Identification of Initiating Trunk Mutations and Distinct Molecular Subtypes: An Interim Analysis of the Mmf Compass Study. <i>Blood</i> , 2015, 126, 722-722.	0.6	4
130	Clarithromycin, pomalidomide, and dexamethasone (ClapD) in relapsed or refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8036-8036.	0.8	4
131	Immunomodulatory agents changing the landscape of multiple myeloma treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, S1-S4.	2.0	3
132	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1885-1893.	0.6	3
133	Daratumumab in Patients with Multiple Myeloma and Renal Impairment - Real-World Data from a Single-Center Institution. <i>Blood</i> , 2019, 134, 5563-5563.	0.6	3
134	BiRD (Biaxin®/Revlimid®/Dexamethasone) Combination Therapy (Rx) Results in High Complete Remissions (CR) and Overall Responses in Myeloma (MM) with Poor Prognostic Features.. <i>Blood</i> , 2005, 106, 642-642.	0.6	3
135	Relationship between Quality of Response to Bortezomib (btz) and Clinical Benefit in Multiple Myeloma (MM) in the APEX and SUMMIT Studies.. <i>Blood</i> , 2006, 108, 3529-3529.	0.6	3
136	First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma. <i>Blood</i> , 2008, 112, 3697-3697.	0.6	3
137	Newly-Diagnosed Multiple Myeloma. <i>Blood</i> , 2013, 122, 3216-3216.	0.6	3
138	Impact of Prior Treatment on Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in a Subgroup Analysis of the Phase 3 Endeavor Study (NCT01568866). <i>Blood</i> , 2015, 126, 729-729.	0.6	3
139	Carfilzomib (K) in relapsed and refractory multiple myeloma (RRMM): Frailty subgroup analysis from phase III ASPIRE and ENDEAVOR.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8028-8028.	0.8	3
140	Impact of Early Response to Sequential High-dose Chemotherapy on Outcome of Patients With Advanced Myeloma and Poor Prognostic Features. <i>Leukemia and Lymphoma</i> , 2002, 43, 607-612.	0.6	2
141	Lenalidomide in renal insufficiency â€œ balancing the risks and benefits: response to Borrello. <i>British Journal of Haematology</i> , 2009, 144, 447-448.	1.2	2
142	Sustained disease control in transplant-ineligible patients: the role of continuous therapy. <i>Leukemia Research</i> , 2012, 36, S19-S26.	0.4	2
143	Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2959-2961.	0.6	2
144	Cellular proliferation by multiplex immunohistochemistry identifies aggressive disease behavior in relapsed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2085-2087.	0.6	2

#	ARTICLE	IF	CITATIONS
145	Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial. <i>EJHaem</i> , 2021, 2, 375-384.	0.4	2
146	Once Weekly Versus Twice Weekly Carfilzomib Dosing in Patients with Relapsed and Refractory Multiple Myeloma (A.R.R.O.W.): Efficacy and Safety Analyzed By Age Group. <i>Blood</i> , 2018, 132, 3277-3277.	0.6	2
147	Updated Survival Analyses after Prolonged Follow-Up of the Phase 2, Multicenter CREST Study of Bortezomib in Relapsed or Refractory Multiple Myeloma.. <i>Blood</i> , 2007, 110, 2717-2717.	0.6	2
148	Summary of treatment-emergent renal events from patients treated with single-agent carfilzomib from four phase II studies in relapsed and/or refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2012, 30, e18569-e18569.	0.8	2
149	Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8525-8525.	0.8	2
150	A phase 1b study of durvalumab (MEDI4736) alone or in combination with pomalidomide (POM) with or without low dose-dexamethasone (LoDEX) in patients (pts) with relapsed and refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS8072-TPS8072.	0.8	2
151	Prospective study to measure the impact of MMprofiler on treatment intention in newly diagnosed multiple myeloma patients (PROMMIS).. <i>Journal of Clinical Oncology</i> , 2019, 37, 8030-8030.	0.8	2
152	Preliminary Results of a Phase 2 Study of PD 0332991 in Combination with Bortezomib and Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2011, 118, 2940-2940.	0.6	2
153	Synergistic Loss of IRF4 and Induction of IRF7 Sensitizes Primary Myeloma Cells to IMiD Killing by IFN $\gamma$ in Prolonged Early G1 Arrest Induced by CDK4/CDK6 Inhibition. <i>Blood</i> , 2012, 120, 572-572.	0.6	2
154	A phase 1 open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-001, an anti-CD74 antibody drug conjugate, in patients with advanced B-cell malignancies.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS7586-TPS7586.	0.8	2
155	Plasma Cell Myeloma Presenting With Amyloid-Laden Crystal-Negative Histiocytosis. <i>American Journal of Clinical Pathology</i> , 2020, 154, 767-775.	0.4	1
156	Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 1554-1562.	2.0	1
157	Host Immune Responses Against CT Antigens in Multiple Myeloma Patients.. <i>Blood</i> , 2006, 108, 3492-3492.	0.6	1
158	Cyclophosphamide Overcomes the Suppressive Effect of Lenalidomide Therapy on Stem Cell Collection in Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma.. <i>Blood</i> , 2007, 110, 3024-3024.	0.6	1
159	A Comparison of Chemotherapy + G-CSF Versus Plerixafor (Mozobil $\text{\textcircled{R}}$ ) + G-CSF for Stem Cell Mobilization In Patients with Multiple Myeloma Treated with Lenalidomide. <i>Blood</i> , 2010, 116, 2258-2258.	0.6	1
160	Induction of Metabolic Impairment In Prolonged Early G1 Arrest Induced by CDK4/CDK6 Inhibition Sensitizes Myeloma Cells for Proteasome Inhibitor Killing During Subsequent S Phase Synchronization. <i>Blood</i> , 2010, 116, 2989-2989.	0.6	1
161	Lenalidomide Targets Myeloma Cells Preferentially During Prolonged Early G1 Arrest but Not Synchronization Into S Phase by Selective and Reversible Inhibition of CDK4/CDK6 through Loss of IRF-4. <i>Blood</i> , 2010, 116, 449-449.	0.6	1
162	A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplant in Multiple Myeloma. <i>Blood</i> , 2011, 118, 2042-2042.	0.6	1

#	ARTICLE	IF	CITATIONS
163	Sensitizing shRNA Screen for Molecular Targets in CDK4/CDK6-Based Combination Therapy in Multiple Myeloma. <i>Blood</i> , 2014, 124, 3440-3440.	0.6	1
164	Newly-Diagnosed Multiple Myeloma. <i>Blood</i> , 2014, 124, 4761-4761.	0.6	1
165	MyPRSR Molecular Subtypes of Multiple Myeloma Represent All High-Risk FISH Translocations Included in the mSMART 2.0 and R-ISS Guidelines. <i>Blood</i> , 2016, 128, 3264-3264.	0.6	1
166	Sequencing of Proteasome Inhibitors in Patients with Multiple Myeloma. <i>Blood</i> , 2016, 128, 4522-4522.	0.6	1
167	Atypical Serum Immunofixation Pattern (ASIP) Development during Induction Therapy with BiRD for Newly Diagnosed Multiple Myeloma Correlates with a High Rate of Complete Remission.. <i>Blood</i> , 2007, 110, 2737-2737.	0.6	1
168	Targeting Cdk4/6 in Combination Therapy Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma through Synergistic Mitochondria Depolarization.. <i>Blood</i> , 2007, 110, 667-667.	0.6	1
169	MAGE-A3 Inhibits p53 and Promotes Proliferation and Survival in Multiple Myeloma.. <i>Blood</i> , 2009, 114, 1795-1795.	0.6	1
170	MAGE-A Inhibits Apoptosis In Proliferating Multiple Myeloma Cells. <i>Blood</i> , 2010, 116, 785-785.	0.6	1
171	The Ki67/CD138 Ratio Independently Predicts Overall Survival in the Upfront Treatment of Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2014, 124, 2016-2016.	0.6	1
172	Rising Plasma Cell Proliferation By Ki67/CD138 Ratio at Relapse Is a Marker of High Risk Disease in Multiple Myeloma. <i>Blood</i> , 2015, 126, 2991-2991.	0.6	1
173	Carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) and early progression during prior therapy: Secondary analysis from the phase 3 study ASPIRE (NCT01080391).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8045-8045.	0.8	1
174	Hematogenous Extramedullary Relapse in Multiple Myeloma - A Multicenter Retrospective Study in 127 Patients. <i>Blood</i> , 2018, 132, 2004-2004.	0.6	1
175	Novel therapies in monoclonal gammopathies. <i>Hematology</i> , 2012, 17, s121-s124.	0.7	0
176	High-Cutoff Hemodialysis in Myeloma Cast Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 2085.	3.8	0
177	High-dose lenalidomide and melphalan as conditioning for autologous stem cell transplantation in relapsed or refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8021-8021.	0.8	0
178	Depsipeptide in the Treatment of Relapsed and Refractory Multiple Myeloma (MM): A Prospective Evaluation of the Cell Cycle.. <i>Blood</i> , 2004, 104, 1497-1497.	0.6	0
179	Selective inhibition of CDK4/CDK6 sensitizes bone marrow myeloma cells for killing by proteasome inhibitors carfilzomib and PR-047 through cell cycle-dependent expression of pro-apoptotic Noxa and Bim.. <i>Blood</i> , 2009, 114, 2854-2854.	0.6	0
180	The Effect of Bortezomib, Cyclophosphamide, and Filgrastim On Complete Remission Rates and CD34+ Stem Cell Collections in Multiple Myeloma.. <i>Blood</i> , 2009, 114, 4349-4349.	0.6	0

#	ARTICLE	IF	CITATIONS
181	Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) Breaks Plateau Responses Following Initial Induction Therapy in Multiple Myeloma: Results of a Phase II Pilot Study.. Blood, 2009, 114, 2311-2311.	0.6	0
182	Updated Report of T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®],) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702	0.6	0
183	T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy in Newly Diagnosed Symptomatic Multiple Myeloma. Blood, 2011, 118, 2937-2937.	0.6	0
184	PET/CT Evaluation As a Prognostic Indicator In Relapsed Or Refractory Multiple Myeloma. Blood, 2013, 122, 1878-1878.	0.6	0
185	Relationship Of Serum Free Light Chain Reduction To Best Overall Response In Phase 2 Single-Agent and Combination Studies Of Carfilzomib In Patients With Relapsed Or Relapsed and/Or Refractory Multiple Myeloma. Blood, 2013, 122, 1965-1965.	0.6	0
186	A Comparison of Outcomes in the First-Line Treatment of Multiple Myeloma Presenting with Single Versus Multiple Monoclonal Paraproteins. Blood, 2014, 124, 2038-2038.	0.6	0
187	Proteasome Inhibitor Treatment in Multiple Myeloma Can Mobilize Hematopoietic Stem Cells in the Absence of G-CSF. Blood, 2014, 124, 2452-2452.	0.6	0
188	Effect of Autologous Transplantation on PFS2 in Myeloma Patients Receiving Front-Line Bird (clarithromycin, lenalidomide, dexamethasone). Blood, 2014, 124, 5778-5778.	0.6	0
189	The Clinical Utility of Bone Resorption and Bone Formation Markers in Multiple Myeloma. Blood, 2015, 126, 5373-5373.	0.6	0
190	Plasma cell proliferation by SynKii multiplex immunohistochemistry (mIHC) for clinical use in multiple myeloma (MM).. Journal of Clinical Oncology, 2016, 34, 8056-8056.	0.8	0
191	IgM Myeloma: A Multicenter Retrospective Study of 159 Patients. Blood, 2016, 128, 3276-3276.	0.6	0
192	Cooperative Suppression of MEIS2 Mediates Dexamethasone Enhancement of Lenalidomide Killing in Myeloma Cells. Blood, 2016, 128, 3292-3292.	0.6	0
193	Comparison of Early Versus Delayed Filgrastim (G-CSF) Administration Following Autologous Stem Cell Transplantation in Patients with Multiple Myeloma - Real-World Data from a Single-Center Institution. Blood, 2019, 134, 5644-5644.	0.6	0
194	Autologous Stem Cell Transplantation Outcomes in Patients with Myeloma and Renal Dysfunction. Blood, 2019, 134, 5573-5573.	0.6	0
195	Harnessing the Epichaperome As a Therapeutic Approach in Multiple Myeloma. Blood, 2019, 134, 4399-4399.	0.6	0
196	532. COVID-19 Pneumonia in Patients with Hematologic Malignancies â€“ A Report from the US Epicenter. Open Forum Infectious Diseases, 2020, 7, S333-S333.	0.4	0
197	Treatment of multiple myeloma with carfilzomib in patients with renal injury. Clinical Advances in Hematology and Oncology, 2013, 11, 605-6.	0.3	0